Glenmark Shares Plunge 6% After USFDA Recalls 39 Drugs

k Pharmaceuticals faced a turbulent day on April 9, 2025, as its shares crashed over 6 percent following a U.S. Food and Drug Administration (USFDA) announcement. The regulator disclosed that 39 drugs, primarily manufactured at the company’s Pithampur plant in Madhya Pradesh, were recalled from the American market due to Good Manufacturing Practice (GMP) concerns. This voluntary recall, initiated by Glenmark on March 13, has sparked a significant sell-off, extending the company’s losses for the fourth consecutive session. The USFDA classified the recall as Class II, indicating that the affected products may cause temporary or medically reversible adverse health consequences, though serious harm is unlikely. Despite the voluntary nature of the recall, investor sentiment took a hit, driving Glenmark’s share price down over 13 percent in the past five trading sessions. The pharma giant, once a darling of the market, is now grappling with mounting pressure as it navigates this setback. The recalled drugs, produced at the Pithampur facility, underscore ongoing challenges for Glenmark in maintaining compliance with stringent U.S. regulatory standards. While the company has not detailed the specific GMP issues, the recall highlights the critical role of quality control in sustaining its foothold in the lucrative U.S. market. This development comes amid a broader wave of scrutiny on Indian pharmaceutical firms, with several facing similar USFDA actions in recent months.